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Summary
High serum cholesterol is an established risk factor for
cardiovascular disease and is the prime target for ther-
apeutic intervention in large groups of patients. The de-
velopment of modern treatments for this major risk fac-
tor was propelled by the early realization that forms of
severe hypercholesterolemia could be caused by domi-
nantly inherited defects in the LDL receptor or in the
APOB gene. Further understanding of the mechanisms
contributing to early atherosclerosis will allow for new
targets for therapy. We therefore identified and investi-
gated the genetics of families from Sardinia that have
recessive inheritance of precocious hypercholesterol-
emia. We used five families in an analysis of linkage of
the autosomal recessive hypercholesterolemia locus,
termed “ARH1,” to chromosome 15q25-q26. A ge-
nomewide search mapped the disease-causing gene with
a LOD score of 3.3 and excluded major contributions
to the phenotype of other genes. A candidate gene pre-
sent in the mapped chromosome region—the ligand-ac-
tivated liver-transcription-factor gene ARP1 (apolipo-
protein regulatory-protein gene)—has been excluded
after DNA sequencing. The close-bred nature of the Sar-
dinian population offers unique opportunities for iso-
lation of this hypercholesterolemia-causing gene.
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Introduction
An elevated plasma concentration of LDL-cholesterol
(LDL-C) is one of the most important quantitative risk
factors for coronary heart disease and is the target for
therapeutic interventions in large groups of patients in
urbanized societies (National Cholesterol Education
Program 1994). Data from family and twin studies have
shown the importance of genetic factors as regulators of
cholesterol concentration (Austin et al. 1987; Bucher et
al. 1988; Perusse et al. 1989; Rice et al. 1991), but only
a few genes and their contributions to increased LDL-
C levels have been characterized. Familial hypercholes-
terolemia (MIM 603813), an autosomal dominant dis-
order, is caused by a defective LDL-receptor gene located
on chromosome 19 and is characterized by high levels
of LDL-C, tendon xanthomas, and premature athero-
sclerosis with precocious cardiovascular disease (Gold-
stein and Brown 1973; Dammerman and Breslow 1995;
Varret et al. 1998). A similar phenotype is observed in
familial defective ApoB (FDB), as a result of a mutation
in the APOB gene on chromosome 2 (Myant 1993).
Recently, in families with dominantly inherited hyper-
cholesterolemia, in which defects in the LDL receptor
or the ApoB protein were excluded, a new hypercho-
lesterolemia locus was mapped to chromosome 1 (Varret
et al. 1999). These observations show the genetic het-
erogeneity of hypercholesterolemia and further empha-
size the complex regulation of the cholesterol concen-
tration.
In 1995, a consanguineous Sardinian family, charac-
terized by members with severe hypercholesterolemia,
was identified (Zuliani et al. 1995). The affected indi-
viduals showed clinical features that were indistinguish-
able from those present in patients with homozygous
LDL-receptor defects. In contrast to heterozygous
individuals with LDL-receptor defects, parents of the
affected members of this family displayed levels of total
cholesterol (total-C), triglycerides (TGs), LDL-C, and
HDL-cholesterol (HDL-C) that were within the normal
range for the Sardinian population. No defects were ob-
served in binding of LDL isolated from patients or in
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Figure 1 Structure of the five Sardinian pedigrees with hypercholesterolemia. Circles denote females; squares, males; blackened
symbols, affected individuals. Double lines indicate consanguineous matings. Numbers below each symbol indicate age at the time of
this study or age at death; numbers inside symbols indicate the number of siblings with an identical phenotype. Stars above symbols
denote individuals included in the linkage analysis.
LDL-receptor–mediated internalization and degradation
of LDL, in fibroblasts from affected individuals. Other
known causes of hypercholesterolemia, such as sitoster-
olemia and defects in ApoB and in ApoE, were excluded
(Zuliani et al. 1995). In contrast, in vivo analysis of the
LDL distribution in patients, compared with that in con-
trol individuals, indicated decreased LDL uptake in the
liver, kidney, and spleen (Zuliani et al. 1999). Although
affected family members display many clinical features
in common with those of patients who are homozygous
for LDL-receptor mutations, the clinical observa-
tions—in particular, the fact that obligate carriers dis-
play normal cholesterol concentrations—suggested that
this family segregated a new genetic form of severe hy-
percholesterolemia that is distinct from hypercholester-
olemia caused by LDL-receptor or ApoB defects. In the
present study, we describe four additional Sardinian fam-
ilies with autosomal recessive hypercholesterolemia
(ARH) that were used for the genetic mapping of the
disease-causing gene, by means of genomewide linkage
analysis.
Families and Methods
Study Families and Diagnosis
The criteria used to select families with ARH for
linkage analysis were as follows: (i) at least one af-
fected family member with precocious debut of the
hypercholesterolemia phenotype (e.g., presence of
high levels of LDL-C in untreated affected individuals
who are following a Western-type diet [Thompson et
al. 1989] and who have tuberous and/or tendon xan-
thomas or have precocious atherosclerosis), and (ii)
obligate carriers (e.g., parents of affected individuals)
who display lipid values within the normal range for
the population. The influence on the cholesterol con-
centration of other diseases—for example, liver, kid-
ney, or thyroid disease—has been considered. The
study was approved by the ethics committee at the
University of Sassari, and all subjects gave informed
oral consent to participation in the study.
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Table 1
Clinical Characteristics of Family Members Affected with Early Hypercholesterolemia
CLINICAL CHARACTERISTICS OF AFFECTED FAMILY MEMBERS



















154 (F) 36 26 23 16.2 14.8 1.24 .55
157 (F) 28 20 14 14.0 12.7 1.16 .71
367:
1326 (M) 9 16 4 12.3 11.2 .90 1.06
1327 (M) 15 20 9 11.0 10.0 .80 1.06
461:
1776 (M) 33 25 10 15.0 13.3 1.45 .97
1777 (F) 30 20 11 13.7 12.3 1.19 1.15
495:
2052 (M) 22 23 11 16.6 15.7 .69 1.26
2053 (M) 17 25 8 13.8 12.9 .72 1.00
496:
2059 (M) 13 23 5 18.2 16.7 1.12 2.08
NOTE.—Lipid plasma concentrations (mean  SD) in the general male population (age 120, )n = 4,552
of Sardinia are as follows: total-C, ; HDL-C, ; LDL-C, ; and TG, (Maioli5.2 1.0 1.3 0.3 3.6 0.9 1.4 0.9
et al. 1989).
a BMI = body-mass index.
Plasma Lipid Analysis
Venous-blood samples were drawn in EDTA-tubes,
after a 12-h overnight fast, and were immediately cen-
trifuged, at 3,000 g, for 15 min. Plasma samples were
stored at 40C, until lipid levels were determined
(Maioli et al. 1989). Plasma LDL-C was calculated by
use of the Friedewald formula, since plasma TGs were
!4.5 mmol/liter (Friedewald et al. 1972).
Genotyping
Genomic DNA was purified from peripheral lympho-
cytes, and 5 ng was amplified, by PCR, in 10 ml con-
taining 0.15 mM each primer, 0.2 mM each dNTP, 1#
buffer (10 mM Tris-HCl, pH 8.8, 1.5 mM MgCl2, 150
mM KCl, and 0.1% Triton X-100), and 0.2 U
DynaZyme. PCR cycles were as follows: 95C for 5 min,
then 35 cycles at 95C for 30 s, and then annealing at
primer-specific temperatures (53C, 55C, and 58C) for
75 s and extension at 72C for 15 s, followed by a final
extension at 72C for 10 min. We used 315 fluorescent
microsatellite markers spanning all chromosomes (Mur-
ray et al. 1994). The PCR products were separated on
4% polyacrylamide gels, by use of an ABI377 Sequencer,
and genotypes were identified by use of ABI GENES-
CAN/GENOTYPER software (PE Biosystems). All gen-
otypes were checked for Mendelian inheritance, both by
inspection and by use of a procedure in GENEHUNTER
(Kruglyak et al. 1996). All inconsistent genotypes were
resolved by repeating the PCR amplification and by typ-
ing the entire family in question for the relevant loci.
The markers D15S652, D15S1004, D15S130, and
D15S816 were typed twice in all subjects, for confir-
mation.
Linkage Analysis
To localize the disease locus, we genotyped all five
families, with the use of 310 markers that were evenly
spaced across the genome and that were selected from
the Cooperative Human Linkage Center (CHLC) da-
tabase. Five additional markers (cen-D15S963,
D15S1004, D15S130, D15S207, and D15S157-tel)
were identified from the Ge´ne´thon map. The chro-
mosomal order of non-CHLC markers was taken from
Ge´ne´thon. The order of all markers on chromosome
15 was checked by use of the program CRIMAP, ver-
sion 2.4; our results did not differ from the Ge´ne´thon
data. The average spacing of microsatellite markers
was 12 cM (range 0.2–37 cM). On chromosome 15,
the average distance between the 16 markers was 6.8
cM (range 0.2–15 cM), and the markers showed an
average heterozygosity of .7 (range .48–.82). In par-
ticular, D15S1004 had a heterozygosity of .66 in a
Sardinian population sample ( ). After analysisn = 60
of all available data (e.g., affected individuals have
parents with cholesterol levels within the normal
range, both sexes are affected, consanguineous mat-
ings occur, and parents originate from the same village
or its vicinity), we selected to calculate linkage, under
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Table 2
Phenotypes of Parents (Heterozygous Carriers) of Patients with Hypercholesterolemia
PHENOTYPES, IN 1999,

















152 (M) 83 24 5.4 3.6 1.6 .8
153 (F) 69 39 5.8 3.9 1.6 1.1
367:
1324 (M) 44 26 6.2 4.9 .8 2.3
1325 (F) 42 20 3.8 2.6 1.1 .7
461:
1774 (M) 67 27 5.9 4.0 1.7 .9
1775 (F) 59 31 4.4 2.7 1.5 .7
495:
2054 (M) 51 29 5.1 3.8 1.1 1.0
2055 (F) 59 24 4.6 3.3 1.1 .9
496:
2060 (M) 45 24 5.1 3.7 1.2 1.1
2057 (F) 41 23 5.1 3.6 1.3 1.0
NOTE.—Data are as in table 1.
a recessive model with full penetrance, no phenocop-
ies, and the assumption of a gene frequency of .001,
by use of GENEHUNTER software (Kruglyak et al.
1996). Two-point linkage analysis was performed by
use of both the MLINK program of the LINKAGE
package and FASTLINK, version 2.2 (Ott 1991; Cot-
tingham et al. 1993).
Sequence of the Apolipoprotein Regulatory-Protein
Gene (ARP1)
Genomic DNA (100 ng) was PCR amplified in 50 ml
containing 0.36 mM each primer, 0.2 mM each dNTP,
0.15 mM 7-deaza-dGTP, 1 # DZB (10 mM Tris-HCl,
pH 8.8, 1.5 mMMgCl2, 150 mM KCl, and 0.1% Triton
X-100), and 1.4 U of DynaZyme. The PCR conditions
were as follows: consisting of 40 cycles for 60 s at 96C,
followed by annealing for 30 s at 52C (for exon 1), at
60C (for exon 2), and at 56C (for exon 3) and then
by extension at 72C for 120 s. The DNA sequence was
determined from 40 ml of PCR product, by use of the
Big Dye Terminator Cycle Sequencing Ready Reaction
Kit (PE Biosystems), and was separated on an ABI377
DNA Sequencer. The DNA sequence of the ARP1 gene
was determined for all nine affected individuals, for one
unaffected family member, and for one unaffected, un-
related individual from Sardinia. The two unaffected in-
dividuals (age 33 years and age 34 years) had normal
lipid values (in particular, LDL-C was !2.6 mmol/liter




Applying the criteria as described above, we identified
four new Sardinian families with ARH. A total of 29
individuals from five families—four families with two
affected offspring each and one family with one affected
offspring—were included in the linkage analysis (fig. 1).
In all families selected, the disease phenotype was in-
herited in a recessive mode; cholesterol levels displayed
bimodal distribution within each family, and affected
individuals had total-C levels 11 mmol/liter, in com-
bination with normal TG levels (table 1). Moreover, par-
ents of affected individuals displayed concentrations of
TGs, total-C, LDL-C, and HDL-C that were within the
normal distribution (table 2).
Linkage Analysis
We applied genomewide linkage analysis, using 310
markers that were evenly spaced throughout the ge-
nome. At the q arm of chromosome 15, a suggestive
LOD score for linkage (LOD score 2.2) was observed,
with the marker D15S816. To extract more data from
the available pedigrees, we elected to type the families
by use of five additional informative markers located in
this region of chromosome 15. Because of the structure
of the pedigrees, the haplotypes cannot be unequivocally
determined in all instances; the haplotypes resolved by
use of GENEHUNTER software are presented in figure
2. When additional markers were added to the linkage
analysis, we were able to map the hypercholesterolemia
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Figure 2 Suggested haplotypes of chromosome 15q24-15qter in families with ARH. The common region shared in affected in-
dividuals within each family is boxed. Displayed haplotypes were calculated by use of the GENEHUNTER program.
locus to 15q25-q26 (figs. 2 and 3). The marker
D15S1004 was the most informative marker in the re-
gion, and it generated a LOD score of 3.3, by use of
two-point linkage analysis. The LOD score remained 13,
even if the penetrance was changed to .9 and/or the
disease-gene frequency was changed to .01. In the region
of 15q25-q26, we identified, from public databases, a
candidate gene—the transcription-factor gene ARP1.
The LOD scores for all chromosomes in the multipoint
analysis are shown in figure 4.
Sequence of ARP1
Comparison of the genomic DNA sequence of ARP1
with published human sequences (Ladias and Karathan-
asis 1991) revealed homozygous differences in intron 1
that were present in the two unaffected individuals as
well. No DNA sequence variants were identified in either
the three exons, the conserved splicing sequences, the
promoter region up to 221, or the 3′ UTR of the gene.
Discussion
In the present report, we have shown that ARH is
linked to a locus, termed “ARH1,” located in the chro-
mosome region 15q25-q26. The initial set of genetic
markers indicated suggestive linkage. A denser set of
markers, including nine markers selected from this re-
gion of the q arm of chromosome 15, showed genome-
wide significance for linkage (LOD score 3.3), by means
of two-point linkage analysis with marker D15S1004.
When multipoint linkage was calculated, the right part
of the largest pedigree (family 461) was removed, as a
result of software limitations. The maximum multipoint
LOD score was therefore 3.05 (fig. 3). At the telomeric
side, a crossover in family 367, between the markers
D15S816 and D15S207, delimited the linked 16-cM re-
gion, and, at the centromeric side, a crossover between
markers D15S963 and D15S652 delimited the region in
family 495. With this set of markers, common haplo-
types were observed within each family but not between
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Figure 3 Multipoint linkage analysis of ARH, displaying chromosome 15 results. Markers are indicated below the X-axis. The
ARP1 gene is located at 15q25-15q26.
families (fig. 2). This could be the result of several fac-
tors, either alone or in different combinations: (i) the
five families come from different geographic regions of
Sardinia that, given the close breeding often observed in
Sardinian villages, have most likely been genetically sep-
arated for a considerable fraction of the time since the
colonization of the Sardinian island; (ii) the disease-car-
rying haplotypes originated outside Sardinia but are de-
tected in the Sardinian population, as a result of the
higher degree of close breeding/inbreeding in combina-
tion with the recessive nature of the disease; and/or (iii)
the available published markers in the linked region do
not permit a map that is dense enough to detect a com-
mon haplotype in Sardinians from different villages,
even though there might be a common origin of the
hypercholesterolemia mutation(s).
With the exception of chromosome 15, no significant
or suggestive indications of linkage to the ARH phe-
notype were revealed by linkage analysis (fig. 4). Par-
ticular emphasis has been placed on genotyping of chro-
mosome regions that contain candidate genes for hy-
percholesterolemia, such as LDLR (19p13.2-p13.1),
APOB, A-I/C-III/A-IV (11q23), HMGCR (5q13.3-q14),
APOE (19q13.2), and LRP (12q13.1-q13.3). None of
the markers flanking these candidate genes showed any
evidence for linkage to the disease, confirming—also
from the genetic point of view—that this disease is dis-
tinct from other known or suspected causes of hyper-
cholesterolemia. Moreover, our data show that ARH in
these five families is not linked to the recently described
familial-hypercholesterolemia locus on chromosome 1,
confirming, for this locus, the negative linkage obtained
for two other Sardinian families with ARH (Varret et
al. 1999).
In the region 15q25-q26, there is one candidate gene,
identified in public databases, that can be connected to
lipid metabolism. The liver transcription factor Arp-1 is
involved in the regulation of APOB and other lipopro-
tein genes (Qiu et al. 1995). Arp-1 was shown to regulate
APOB transcription, acting either alone or with other
transcription factors. Moreover, that Arp-1 is one of
several regulators of transcription in hepatic cells sug-
gests that the effect on APOB transcription could depend
on their relative intracellular levels and/or affinities (Ma-
lik and Karathanasis 1995). In conclusion, both the doc-
umented activity of Arp-1 as a repressor or an activator
of hepatic apolipoprotein-gene transcription and the ob-
servation that this form of hypercholesterolemia is ex-
pressed mainly as an LDL-catabolism defect in hepa-
tocytes (Zuliani et al. 1999) have led us to investigate
the structure of the gene in some detail. The analysis of
the ARP1 sequence in affected members did not reveal
any DNA-sequence variation in either the three exons
or their conserved splicing sequences, in the promoter
region, or in the 3′ UTR of the gene. These results make
it unlikely that ARP1 is involved in the hypercholester-
olemia phenotype.
Other reported cases of ARH not linked to LDLR or
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Figure 4 Multipoint-linkage-analysis data for all chromosomes except the sex chromosomes. LOD scores 12 are hidden and
indicate that the chromosome region is excluded for linkage. Chromosome X was excluded by single-point analysis, with use of LINKAGE
software, version 5.1.
APOB suggest the existence of as-yet-unknown genes for
hypercholesterolemia (Sirtori et al. 1991; Harada-Shiba
et al. 1992; Schmidt et al. 1998). In these families, the
hypercholesterolemia phenotype—expressed as elevated
LDL-C, xanthomas, or coronary heart disease—was not
reported in parents.
The data presented in this report support the notion
that this form of ARH is the result of an as-yet-unknown
gene, at chromosome 15q25-q26, that has a major effect
on cholesterol metabolism and atherosclerosis etiology.
In addition, our results provide genetic evidence in sup-
port of the notion that ARH1 is a distinct form of mono-
genic hypercholesterolemia.
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